Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, CA / ACCESSWIRE / January 2, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified...
Clinical Trial
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study...
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Coherus Announces U.S. Launch of LOQTORZI™
LOQTORZI™ (toripalimab-tpzi) LOQTORZI™ (toripalimab-tpzi) product image – Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all...
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
$95 million in development milestones payable over two years, as part of GSK license agreementCAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE...
Umoja Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to...
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has...
Jasper Therapeutics, Inc. Announces Reverse Stock Split
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s diseaseBETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) --...
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical studySAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE)...
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Court Finds Corcept Therapeutics’ Patents Not Infringed
MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE)...
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and...
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences
MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell therapies, announced today...
XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...